Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 9/20 | 0.52 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | RPS27 | P42677 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17396693 | 0.88 | GLS (0.54) | GLSDEGS1CACNA1GCACNA1IELOVL1 | |
| SCHEMBL28803970 | 0.84 | GLS (0.43) | GLS | |
| SCHEMBL14986958 | 0.83 | GLS (0.60) | GLSDEGS1CACNA1GCACNA1IELOVL1 | |
| SCHEMBL29679027 | 0.82 | GLS (0.53) | GLS | |
| SCHEMBL15728060 | 0.82 | GLS (0.53) | GLS | |
| SCHEMBL14986962 | 0.78 | GLS (0.60) | GLSDEGS1CACNA1GCACNA1IELOVL1 | |
| SCHEMBL14975908 | 0.76 | GLS (0.81) | GLS | |
| SCHEMBL17395550 | 0.76 | ELOVL1 (0.44) | GLSDEGS1CACNA1GCACNA1IELOVL1 | |
| SCHEMBL17390786 | 0.73 | GLS (0.39) | GLSDEGS1CACNA1GCACNA1IELOVL1 | |
| SCHEMBL17404993 | 0.72 | ABL1 (0.48) | GLSDEGS1CACNA1GCACNA1IELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954686-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | Calithera Biosciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-2920168-B1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| EP-2782570-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9938267-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2014-12-18 | — | — | US | disclosed |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014078645-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3716/4885CACNA1G 4054/4885 |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3703/4885CACNA1G 3968/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3703/4885CACNA1G 3968/4885 |
| US-20140194421-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3716/4885CACNA1G 4054/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3703/4885CACNA1G 3968/4885 |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3716/4885CACNA1G 4054/4885 |
| US-20140369961-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3703/4885CACNA1G 3968/4885 |
| US-20150004134-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3392/4885CACNA1G 4167/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885DEGS1 3703/4885CACNA1G 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.